MULTIPLE MYELOMA

This study aims to find the best COVID-19 booster strategy for people with weakened immune systems, such as those with HIV, organ transplants, or certain cancers. It will compare giving one versus two extra doses of approved mRNA vaccines to see which is safer and triggers a stro…

This study is testing a treatment plan for older adults newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It adds the drug daratumumab to a standard three-drug combination for initial treatment, then continues it as a long-term maintenance the…

This is an early-phase safety study testing a new type of CAR-T cell therapy called MCARH109 for people with advanced multiple myeloma that has come back after several other treatments. Doctors take a patient's own immune cells, modify them in a lab to target a protein called GPR…

This study is for people with multiple myeloma, a blood cancer, that has come back or stopped responding to prior treatments. It aims to see if a new combination of two drugs, teclistamab and daratumumab, works better and is safer than two different standard drug combinations. Ab…

This study is testing whether two drugs, plinabulin and pegfilgrastim, can help white blood cells recover faster after a stem cell transplant for multiple myeloma. The goal is to reduce the time patients have very low white blood cell counts, which increases infection risk. Resea…

This study is testing whether a single infusion of a personalized immune cell therapy (CAR-T) can better control multiple myeloma than standard long-term drug maintenance. It involves 743 adults newly diagnosed with this blood cancer who are not planning an initial stem cell tran…

This is an early-stage study testing whether two targeted cancer drugs, dabrafenib and trametinib, can help control multiple myeloma that has come back or stopped responding to other treatments. The study will enroll about 30 adults whose cancer has a specific genetic change (in …

This study is testing an experimental antibody drug called TNB-383B for people with multiple myeloma that has come back or stopped responding to at least three previous treatments. Researchers are giving the drug to 220 participants to find the safest and most effective dose, and…

This study is testing a new, more stable version of a standard chemotherapy drug called melphalan. It is for adults with multiple myeloma or AL amyloidosis who are getting a stem cell transplant. The goal is to see if this new formulation can be dosed more precisely and cause few…

This study is testing whether a CAR-T cell therapy called cilta-cel can safely treat people with high-risk smoldering myeloma, an early stage of blood cancer that hasn't yet caused symptoms. Researchers are giving 20 participants this immune therapy, which involves modifying thei…

This study is for people with multiple myeloma whose cancer has responded well to initial treatment. It compares two different maintenance drugs—lenalidomide (the usual approach) and daratumumab—to see which one gives patients a better quality of life during long-term treatment. …

This study is testing a combination of four medications—isatuximab, pomalidomide, elotuzumab, and dexamethasone—for adults with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see if this four-drug mix is safe and more ef…

This study is testing a combination of two oral drugs, mirdametinib and sirolimus, for people with advanced multiple myeloma that has returned or stopped responding to many other treatments and has specific genetic changes (KRAS or NRAS mutations). The goal is to find a safe dose…

This study aims to see if multiple myeloma patients who show no detectable cancer after stem cell transplant can safely stop their long-term maintenance medications. Researchers will use advanced blood and imaging tests to identify patients with the lowest possible cancer levels.…

This study is testing a two-part strategy for adults newly diagnosed with multiple myeloma. After initial treatment, patients receive different drug combinations based on whether tiny amounts of cancer cells are still detectable. The goal is to see if these combinations can elimi…

This study is testing a combination of three drugs—bortezomib, lenalidomide, and dexamethasone—for people newly diagnosed with multiple myeloma, a cancer of plasma cells. The main goals are to find the safest dose of the drug combination and to see how well it works to control th…

This is an early-stage study to find the safest, highest dose of a new injectable drug (sotatercept) when combined with two existing oral medications for multiple myeloma. It involves 33 adults whose cancer has returned or stopped responding to prior therapy. The main goal is to …

This early-stage study is testing the safety and best doses of a new drug called teclistamab when it is given alongside other existing cancer drugs. It involves 140 adults with multiple myeloma, a type of blood cancer, who have tried other treatments. The main goal is to see if t…

This large study aims to determine if a newer personalized cell therapy (CAR-T) works better than the current standard stem cell transplant for people newly diagnosed with multiple myeloma. About 750 participants will receive initial chemotherapy, then be randomly assigned to rec…

This study is testing whether adding the experimental drug isatuximab to three standard chemotherapy drugs is safe and effective for people newly diagnosed with multiple myeloma. The trial involves 52 participants who are eligible for a stem cell transplant. Researchers want to s…

This early-stage study is testing a new oral drug called CFT7455 (cemsidomide) for people with non-Hodgkin's lymphoma or multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose and see if the drug helps shrink tumors. …

This study is testing a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma, a cancer of plasma cells in the bone marrow. The main goal is to see how many patients achieve a deep remission (complet…

This early-stage study is testing several combinations of new and existing drugs for people with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to find safe dose levels and check for early signs that the treatments work. The st…

This study is testing whether combining four medications (daratumumab, carfilzomib, lenalidomide, and dexamethasone) is safe and effective for people newly diagnosed with multiple myeloma, a type of blood cancer. Researchers will enroll 75 participants to see if this combination …

This study is testing a single infusion of a patient's own genetically modified immune cells (called CART-ddBCMA) to fight multiple myeloma that has returned or stopped responding to other treatments. It aims to see how well this one-time therapy controls the cancer and how safe …

This study compares two maintenance treatments for multiple myeloma patients who have received a stem cell transplant. Researchers want to see if a three-drug combination (carfilzomib, lenalidomide, dexamethasone) works better than lenalidomide alone at preventing the cancer from…

This study is testing a combination of three drugs—ixazomib, pomalidomide, and dexamethasone—for people with multiple myeloma that has returned or stopped responding to prior treatments. The main goals are to find the safest dose of this combination and to see how well it control…

This early-stage trial is testing the safety of a new treatment called CAR T-cell therapy for people with advanced multiple myeloma, a type of blood cancer. Doctors modify a patient's own immune cells to better target and fight the cancer cells. The study also explores whether ad…

This study is monitoring the safety and real-world effectiveness of the drug Elranatamab in Korean patients with advanced multiple myeloma. It will enroll about 150 adults who have already received at least three prior treatments for their cancer. The goal is to gather informatio…

This small, early-stage study is testing whether a drug called romosozumab can help strengthen bones and slow bone damage in postmenopausal women who have both multiple myeloma and osteoporosis. Researchers will measure changes in bone health markers and closely monitor safety. T…

This study observes how well a drug combination works for adults with multiple myeloma that has returned or stopped responding to previous treatments. Researchers will track 75 patients' quality of life, side effects, and treatment effectiveness in real-world clinic settings, not…

This study is testing if a standard four-drug treatment for multiple myeloma works just as well when given on a simpler, once-a-week schedule instead of twice a week. It involves 39 adults newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The main…

This early-stage study aimed to understand how a drug for relapsed multiple myeloma is processed by the body in people with different levels of liver function. It planned to compare participants with normal liver function to those with impaired function. The study was withdrawn b…

This study is testing whether adding a drug called daratumumab to a three-drug combination works better for controlling newly diagnosed multiple myeloma. Researchers want to see if this four-drug combination is safer and more effective than the standard three-drug treatment. The …

This study tests whether an intensive treatment approach works better for people with newly diagnosed multiple myeloma, especially those with high-risk genetic features. The treatment involves high-dose chemotherapy with stem cell transplants, followed by long-term maintenance me…

This study is testing whether adding a drug called selinexor to existing multiple myeloma treatments can help patients whose cancer has returned or stopped responding to their current therapy. The trial involves 96 adults with multiple myeloma that has progressed despite treatmen…

This study is tracking patients for 15 years after they received an experimental cell therapy called P-BCMA-101 for multiple myeloma, a type of blood cancer. The goal is to monitor for any long-term side effects and see how well the treatment continues to work over time. It is fo…

This study is testing whether a new drug called belantamab mafodotin works better than the current standard treatment for people with multiple myeloma that has come back or stopped responding to other therapies. About 325 participants will be randomly assigned to receive either t…

This study is testing whether a new drug called elranatamab can help control multiple myeloma in people whose cancer has come back or stopped responding to several standard treatments. The drug works by guiding the body's own immune cells to find and attack the cancer cells. The …

This study is testing a combination of four existing drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) for people with multiple myeloma whose cancer has returned or stopped responding to prior treatment. The goal is to see if this specific mix can better contro…

This study tests whether adding the drug daratumumab to standard lenalidomide maintenance therapy helps control multiple myeloma better than lenalidomide alone. It involves 200 people who recently had a stem cell transplant for newly diagnosed multiple myeloma but still show tiny…

This study is testing whether adding the drug ixazomib to two other medications (lenalidomide and dexamethasone) can help control multiple myeloma longer in people who have already received initial treatment. About 160 adults with multiple myeloma who completed prior therapy will…

This early-stage study is testing whether combining three drugs—belantamab mafodotin, nirogacestat, and pomalidomide—is safe for people with multiple myeloma that has returned or stopped responding to previous treatments. Researchers are enrolling just 9 participants who have alr…

This program provided early access to the experimental drug teclistamab for patients with advanced multiple myeloma who had exhausted all standard treatment options. The program was designed for individuals who weren't eligible for clinical trials but had no other approved treatm…

This study is testing whether adding a fourth drug called daratumumab to a standard three-drug combination works better for people newly diagnosed with multiple myeloma who aren't planning an immediate stem cell transplant. Researchers want to see if the four-drug combination hel…

This study is testing different combinations of medications for older adults (65-80 years) who have newly diagnosed multiple myeloma and cannot undergo a stem cell transplant. Researchers want to see if adding certain drugs to standard treatment helps control the cancer better an…

This study is testing whether adding a newer drug called daratumumab to the standard 'Total Therapy' approach helps patients with high-risk multiple myeloma live longer without their cancer getting worse. The trial involves 50 newly diagnosed patients who will receive the drug co…

This study observes Chinese adults with multiple myeloma who switch from their initial treatment to a medication called ixazomib. Researchers will follow about 80 patients for up to 2 years to see how well the treatment works and what side effects occur. The goal is to understand…

This early-stage study is testing the safety and initial effectiveness of a new oral drug called LOXO-338 for patients with advanced blood cancers like leukemia and lymphoma who have already received standard therapies. The trial has two parts: first testing LOXO-338 alone, and t…

This study is testing an experimental treatment called JNJ-68284528, a type of CAR-T cell therapy, for people with multiple myeloma, a cancer of plasma cells. The treatment involves genetically modifying a patient's own immune cells to target and kill cancer cells that carry a ma…

This study tested a combination of four medications for adults newly diagnosed with multiple myeloma, a blood cancer. The goal was to see if adding a newer drug called carfilzomib to an existing three-drug regimen could better control the disease and improve patient outcomes. Res…

This early-stage study is testing the safety and finding the right dose of a four-drug combination for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if combining these medications can better control th…

This study is testing a combination of four medications (daratumumab, carfilzomib, lenalidomide, and dexamethasone) as the first treatment for people newly diagnosed with multiple myeloma, a cancer of plasma cells in the bone marrow. It aims to see how well this combination works…

This study is testing a combination of three drugs for multiple myeloma that has returned or stopped responding to prior treatments. It specifically aims to see if using lower doses of two of the drugs is safe and effective for older patients or those who are too frail for standa…

This study aims to determine which maintenance therapy works better to control multiple myeloma after a stem cell transplant. Researchers are comparing patients who receive one maintenance drug versus those who receive two drugs together. The study will track 69 patients to see w…

This early-stage study is testing the safety and best dose of a two-drug combination for people with multiple myeloma that has returned or stopped responding to prior treatments. The trial combines an antibody-drug therapy with an immunotherapy drug. It aims to see if this combin…

This early-stage study is testing whether two new drugs, XmAb24306 and cevostamab, can be safely given together to people with advanced multiple myeloma that has returned or stopped responding to other treatments. The trial will enroll about 90 patients who have already tried at …

This early-stage study aimed to find the safest and most effective dose of the chemotherapy drug bendamustine for people with multiple myeloma who had been treated before. Researchers planned to give increasing doses to small groups of patients to see how much they could tolerate…

This study directly compares two different three-drug combinations for people newly diagnosed with multiple myeloma, a blood cancer. It aims to find out which treatment regimen is better at keeping the cancer from progressing and helps patients live longer without their disease g…

This large study is testing whether adding a new drug called isatuximab to standard treatment improves outcomes for people newly diagnosed with multiple myeloma, a blood cancer. It involves 662 participants who will receive either the standard three-drug combination or that same …

This study is testing a new combination of two drugs, talquetamab and teclistamab, for people with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe and effective dose, check for side effects, and see how well the com…

This study is testing whether adding a drug called selinexor to a standard three-drug combination works better for people with high-risk, newly diagnosed multiple myeloma. It will compare the new four-drug combination (Dara-SVD) against the current standard four-drug treatment (D…

This study is testing a new combination of four drugs for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see how well this weekly treatment regimen controls the cancer and leads to deep remission. About 50 participants wil…

This study is testing different dosing schedules for the drug belantamab mafodotin in patients with advanced multiple myeloma that has returned or stopped responding to other treatments. The main goal is to see if changing the dose or timing can reduce serious eye-related side ef…

This study compares two different three-drug combinations for people with multiple myeloma that has returned or stopped responding to previous treatments. It aims to see which combination works better at controlling the cancer, is safer, and improves patients' quality of life. Th…

This is an early-stage study testing the safety of a new cell therapy for adults with multiple myeloma that has come back or stopped responding to standard treatments. Doctors take a patient's own immune cells (T-cells), modify them in a lab to better recognize and attack cancer …

This study is testing a new drug called CC-220 for people with multiple myeloma, a type of blood cancer. Researchers want to find the safest and most effective dose, both when given alone and when combined with other standard cancer treatments. The trial includes people whose can…

This large, late-stage trial aims to find out which of two three-drug combinations works better to control newly diagnosed multiple myeloma in patients who cannot undergo intensive stem cell transplant. It directly compares a standard chemotherapy pair (melphalan and prednisone) …

This early-stage study is testing the safety and initial effectiveness of an experimental antibody called CLN-619 in adults with multiple myeloma that has returned and stopped responding to standard treatments. The main goals are to find a safe dose and see if the treatment can s…

This early-stage study aims to find safe doses and check side effects when combining the investigational drug talquetamab with other approved myeloma treatments. It involves 166 participants who have multiple myeloma that has returned or stopped responding to prior therapies. The…

This study is testing an experimental drug called iopofosine I 131 in people with various advanced B-cell blood cancers that have come back or stopped responding to standard treatments. The drug is designed to deliver radiation directly to cancer cells. The main goal is to see if…

This study is for people with multiple myeloma who have had a stem cell transplant. It tests whether adding a drug called daratumumab to the standard maintenance drug lenalidomide is better at keeping the cancer from coming back. A key part of the study uses a very sensitive bloo…

This early-stage study is testing whether a drug called itacitinib can make stem cell transplants safer for older patients with blood cancers. The goal is to prevent a severe, potentially life-threatening immune reaction called cytokine release syndrome (CRS) that can occur after…

This study tests an experimental drug called cevostamab for people with advanced multiple myeloma that has returned or stopped responding to other treatments. It involves 90 participants who have already tried specific targeted therapies. The main goals are to see if the drug hel…

This early-stage study is testing whether combining an experimental drug called TTI-622 with an existing myeloma treatment (daratumumab) is safe for people whose cancer has returned or stopped responding to other therapies. Researchers will first find the highest safe dose of the…

This study aims to see if a new injectable drug called elranatamab works better than the standard oral medication lenalidomide for keeping multiple myeloma under control after a stem cell transplant. It involves 811 people recently diagnosed with this blood cancer who have alread…

This study is testing a three-drug treatment called IRD given after a patient's own stem cell transplant for multiple myeloma. The goal is to help patients stay disease-free for a longer time after their transplant. After the initial treatment, patients receive ongoing 'maintenan…

This study is testing the safety and effectiveness of adding a new drug, belantamab mafodotin, to a standard three-drug combination (VRd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this four-drug combination…

This study is testing a combination of four drugs (carfilzomib, lenalidomide, vorinostat, and dexamethasone) for adults with multiple myeloma that has returned or stopped responding to prior treatment. The main goals are to find the safest dose and see if this powerful combinatio…

This study is testing different sequences of newer immunotherapy drugs for people with newly diagnosed, standard-risk multiple myeloma. Researchers want to see if these treatment combinations can lead to long-term disease control with no detectable cancer cells remaining. The stu…

This early-stage study is testing the safety and best dosing schedule of a new drug called belantamab mafodotin when added to standard chemotherapy for adults newly diagnosed with multiple myeloma. The trial is specifically for patients who are not candidates for intensive stem c…

This study is testing whether adding a personalized immune cell therapy (called ide-cel) to standard maintenance medication (lenalidomide) works better than the standard medication alone for adults with newly diagnosed multiple myeloma. It focuses on patients who had a stem cell …

This trial tests combination therapies with the oral drug iberdomide for patients with multiple myeloma who still have tiny amounts of cancer detectable after a stem cell transplant. The goal is to use these drug combinations to eliminate these remaining cancer cells and achieve …

This study allows patients already receiving venetoclax in other trials to continue treatment if they are benefiting and tolerating it well. The main goal is to collect long-term safety information by tracking any side effects. It includes about 165 patients with various blood ca…

This study is testing whether two drugs, palifermin and leuprolide acetate, can help a patient's immune system recover more quickly after receiving a stem cell transplant from a donor. The transplant is for patients with blood cancers like leukemia or lymphoma. Researchers want t…

This program provides access to an investigational drug called REGN5458 for patients with advanced multiple myeloma who have exhausted all approved treatments. It is a 'compassionate use' program, meaning it is for individual patients in urgent need, not a formal clinical trial. …

This study is testing a combination of two drugs, belantamab mafodotin and isatuximab, for people with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose for the combination and to see how well it works at control…

This study is testing a combination of four chemotherapy drugs to treat a more aggressive form of multiple myeloma, a blood cancer. The main goal is to see if this treatment can make the cancer undetectable in blood tests and keep it that way for at least a year. It is for newly …

This study is testing the safety and effectiveness of a combination of two immunotherapy drugs, ciltacabtagene autoleucel (a CAR-T cell therapy) and talquetamab, for people with high-risk multiple myeloma that has come back after several prior treatments. The main goal is to see …

This early-stage study is testing the safety and dosing of an experimental drug called forimtamig in people with advanced multiple myeloma that has returned or stopped responding to standard treatments. The trial will enroll about 225 participants who have exhausted other options…

This early-phase study is testing a new three-drug combination (iberdomide, elotuzumab, and dexamethasone) for adults with multiple myeloma that has come back or stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to see ho…

This study is testing whether adding a newer drug (daratumumab) to a standard treatment (lenalidomide) works better and is easier to tolerate than the current standard for frail, older adults with newly diagnosed multiple myeloma. The goal is to help control the cancer for a long…

This study is testing whether adding a drug called daratumumab to a standard three-drug combination works better for people newly diagnosed with multiple myeloma, a cancer of plasma cells in the bone marrow. It will involve about 709 participants who are eligible for a stem cell …

This is an early-stage study to test the safety of a new drug called HPN217 (or MK-4002) for people with multiple myeloma that has come back or stopped responding to other treatments. Researchers will give increasing doses to about 100 participants to find the highest dose that i…

This study is testing a flexible treatment strategy for older adults with newly diagnosed multiple myeloma, a blood cancer. Patients first receive a two-drug combination, and doctors then adjust their treatment based on how well they respond. The goal is to control the disease ef…

This large national trial is testing whether choosing cancer drugs based on the specific genetic changes found in a patient's tumor is more effective than standard approaches. It is for adults with advanced solid tumors, lymphoma, or multiple myeloma that have progressed after at…

This study is testing whether a new personalized immune cell therapy (called cilta-cel) works better than current standard drug combinations for people with multiple myeloma that has come back and is resistant to a common treatment. About 419 participants whose cancer has progres…

This study compares two standard drug combinations, with or without an additional medication called daratumumab, for older adults with multiple myeloma who cannot receive a stem cell transplant. It aims to find which treatment works best in everyday clinical practice, focusing on…

This study is testing if adding two oral medications, lenalidomide and CC-486, to standard radiation therapy is safe and effective for treating plasmacytoma, a type of bone tumor related to multiple myeloma. It aims to see if this combination can better control the disease. The t…

This study is testing whether a combination of three drugs (isatuximab, lenalidomide, and dexamethasone) can eliminate tiny amounts of remaining cancer cells in multiple myeloma patients who have already received a stem cell transplant. The trial will enroll 30 adults who still s…

This study is testing a new drug called elranatamab in combination with other cancer therapies for people with multiple myeloma that has come back or stopped responding to several prior treatments. The main goals are to find the safest and most effective dose and to see if these …

This study is testing whether combining four already-approved drugs works better together for people with multiple myeloma that has returned or stopped responding to other treatments. It will involve about 52 adults whose cancer has progressed despite previous therapies. The main…

This study tested if adding an experimental drug called BL-8040 to the standard medication (G-CSF) helps collect more stem cells from patients with multiple myeloma. The goal is to gather enough healthy stem cells for a patient's own transplant (autologous transplant), a key part…

This large study aims to determine if a powerful three-drug combination is just as good as that same combination followed by a stem cell transplant for treating newly diagnosed multiple myeloma in patients up to age 65. It directly compares the effectiveness and side effects of t…

This early-stage trial is testing a new drug called cevostamab, both by itself and in combination with other approved myeloma medications. It aims to find safe doses and see if these treatments can help control multiple myeloma that has returned or stopped responding to other the…

This early-stage study is testing whether adding an experimental drug called TAK-079 to standard multiple myeloma treatments is safe and tolerable. The trial involves about 50 adults with newly diagnosed multiple myeloma who are not planning to get a stem cell transplant right aw…

This early-stage trial is testing a combination of four different drugs for people with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose and see how well the body tolerates the combination. It will involve a sma…

This study is testing a targeted cancer drug called belantamab mafodotin, both by itself and in combination with several other anti-cancer drugs. It aims to find safe and effective treatment options for adults with multiple myeloma that has returned or stopped responding to prior…

This study is testing a new AI tool designed to analyze pictures of cancer cells from patients with multiple myeloma. The goal is to see if the AI can accurately predict which patients have high-risk genetic abnormalities by looking at the shape and features of their cells. If su…

This study tests whether treating people with high-risk smoldering multiple myeloma—a pre-cancer condition—with a three-drug combination can prevent or delay progression to active cancer. Fourteen participants receive injections and infusions of daratumumab, carfilzomib, and dexa…

This study aimed to see if regular clinic visits and a pneumonia vaccine could help prevent infections in cancer patients after they received CAR-T cell therapy. The plan was to enroll 50 adults with blood cancers or solid tumors who were getting this specialized treatment. Resea…

This study is testing whether one or two doses of a pneumonia vaccine works better for people with multiple myeloma, a blood cancer that makes them vulnerable to serious infections. Researchers at National Taiwan University Hospital are comparing the two approaches in 101 patient…

This study is testing whether adding acupuncture to standard pain care can help patients with blood cancers use fewer opioid painkillers during intense chemotherapy. About 300 adults with multiple myeloma, Hodgkin's, or non-Hodgkin's lymphoma will be randomly assigned to receive …

This study is testing a mobile phone app called THRIVE-M, designed to help people living with multiple myeloma. The app provides mental and emotional support to improve quality of life, reduce distress, and ease fatigue. Researchers are comparing the app's effects to standard car…

This study is testing whether a 12-week personalized exercise program is practical and helpful for people living with multiple myeloma, a type of blood cancer. It aims to see if tailored workouts can improve physical fitness, balance, and overall quality of life. The program is c…

This study is testing if a drug called siltuximab can reduce the severe fatigue, pain, and nausea that often follow a stem cell transplant. It focuses on patients aged 60-75 with multiple myeloma or AL amyloidosis. The goal is to block a specific protein linked to inflammation, a…

This study is testing whether a drug called siltuximab can help control two serious side effects that sometimes occur after CAR-T cell therapy for blood cancers. CAR-T therapy can cause dangerous immune overreactions called cytokine release syndrome (CRS) and neurological problem…

This study is testing whether a drug called budesonide can prevent or reduce severe diarrhea in people with multiple myeloma who are undergoing a stem cell transplant. About 120 participants will be randomly assigned to receive either budesonide or a placebo, in addition to their…

This study is testing whether using a digital health platform called All4Cure helps people with multiple myeloma feel more in control of their health. About 200 participants will fill out surveys over a year to measure their engagement and symptom burden. The goal is to see if th…

This study collects blood and bone marrow samples from people with multiple myeloma and related blood cancers to build a research database. Participants also provide medical history through a questionnaire. The goal is to help scientists understand these diseases better and devel…

This is a long-term observational study designed to understand if exposures common in farming—like pesticides, fuels, and dust—increase the risk of developing cancer and other diseases. It follows nearly 90,000 licensed pesticide applicators and their families in Iowa and North C…

This study is testing a new system designed to give doctors a more complete picture of an older patient's overall health and life circumstances when planning cancer treatment. It combines questions about aging, daily function, mental health, and social needs like housing and food…

This study follows people for up to 15 years after they received CAR T-cell gene therapy for blood cancers like lymphoma and leukemia. Researchers check in annually through clinic visits, phone calls, or emails to monitor for any long-term side effects or health issues. The study…

This study aims to find a more precise blood test to predict which patients with chronic lymphocytic leukemia or multiple myeloma are at highest risk for getting infections. Researchers will analyze blood samples from about 150 adults with these cancers over two years, looking fo…

This study aims to better understand the real-world symptoms and treatment experiences of adults with certain cancers. About 100 participants with breast, lung, gastrointestinal cancer, or multiple myeloma will complete weekly digital surveys about their symptoms for at least 12 …

This study aims to understand why certain cancers develop at younger ages in people from different racial and ethnic backgrounds. Researchers will collect tumor tissue and blood samples from 2,400 patients during their regular cancer surgeries. By analyzing these samples, they ho…

This study is monitoring the safety of the drug lenalidomide in older adults with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. It will compare the rate of heart problems and other side effects in patients taking lenalidomide versus those takin…

This study aims to understand why some patients with relapsed multiple myeloma don't receive advanced cellular therapies like CAR-T treatments or stem cell transplants. Researchers will follow 49 patients and their doctors to track referral patterns and treatment decisions. The g…

This study observes how approved multiple myeloma treatments work in everyday clinical practice, not in controlled trials. It follows over 2,500 patients who are already receiving standard treatments for either newly diagnosed or relapsed disease. Researchers track survival, trea…